The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation

Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with valsartan in an outpatient practice.Material and...

Full description

Bibliographic Details
Main Authors: A. S. Ryazanov, E. V. Shikh, O. V. Kechina, M. V. Makarovskaya, A. A. Kudryavtsev
Format: Article
Language:English
Published: Столичная издательская компания 2023-01-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/2853
_version_ 1797232054010642432
author A. S. Ryazanov
E. V. Shikh
O. V. Kechina
M. V. Makarovskaya
A. A. Kudryavtsev
author_facet A. S. Ryazanov
E. V. Shikh
O. V. Kechina
M. V. Makarovskaya
A. A. Kudryavtsev
author_sort A. S. Ryazanov
collection DOAJ
description Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with valsartan in an outpatient practice.Material and Methods. The study included 90 patients with chronic FMR, who were observed for 12 months. They received sacubitril/valsartan or valsartan. Efficiency criteria were: the difference between groups in scores according to the Kansas questionnaire for patients with cardiomyopathy; MR degree parameters (change in effective regurgitation orifice area, vena contracta width, MR volume and MR fraction); indicators of the severity of myocardial remodeling (left ventricular EF; the level of N-terminal brain natriuretic propeptide), exercise tolerance based on a 6-minute walk test, a change in the functional class of heart failure according to NYHA.Results. In a treatment efficacy analysis, the Kansas City Cardiomyopathy Questionnaire–Overall Summary Score improved by 22.1 points in the sacubitril/valsartan group and by 4.5 points in the valsartan group (p<0.001). EF, exercise tolerance, and the number of patients transitioning from NYHA functional class III to II increased in the sacubitril/valsartan group (p<0.05). Also, in this group, the effective area of the regurgitation opening, the width of the vena contracta, the volume of regurgitation, the fraction of regurgitation, and the level of N-terminal brain natriuretic propeptide (p<0.05) decreased more pronouncedly (p<0.05).Conclusion. Compared with valsartan, treatment with sacubitril/valsartan leads to a significant improvement in the quality of life in patients with FMR and HF with reduced EF, which is largely associated with a change in NT-proBNP, echocardiographic characteristics of the severity of MR and the degree of myocardial remodeling.
first_indexed 2024-03-08T14:00:32Z
format Article
id doaj.art-d998a9f966e8435e81c6044e7873cba0
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-04-24T15:54:10Z
publishDate 2023-01-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-d998a9f966e8435e81c6044e7873cba02024-04-01T07:43:43ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532023-01-0118666266810.20996/1819-6446-2022-12-052079The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral RegurgitationA. S. Ryazanov0E. V. Shikh1O. V. Kechina2M. V. Makarovskaya3A. A. Kudryavtsev4I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Clinical and diagnostic center №4 of the Moscow Department of HealthClinical and diagnostic center №4 of the Moscow Department of HealthI.M. Sechenov First Moscow State Medical University (Sechenov University)Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with valsartan in an outpatient practice.Material and Methods. The study included 90 patients with chronic FMR, who were observed for 12 months. They received sacubitril/valsartan or valsartan. Efficiency criteria were: the difference between groups in scores according to the Kansas questionnaire for patients with cardiomyopathy; MR degree parameters (change in effective regurgitation orifice area, vena contracta width, MR volume and MR fraction); indicators of the severity of myocardial remodeling (left ventricular EF; the level of N-terminal brain natriuretic propeptide), exercise tolerance based on a 6-minute walk test, a change in the functional class of heart failure according to NYHA.Results. In a treatment efficacy analysis, the Kansas City Cardiomyopathy Questionnaire–Overall Summary Score improved by 22.1 points in the sacubitril/valsartan group and by 4.5 points in the valsartan group (p<0.001). EF, exercise tolerance, and the number of patients transitioning from NYHA functional class III to II increased in the sacubitril/valsartan group (p<0.05). Also, in this group, the effective area of the regurgitation opening, the width of the vena contracta, the volume of regurgitation, the fraction of regurgitation, and the level of N-terminal brain natriuretic propeptide (p<0.05) decreased more pronouncedly (p<0.05).Conclusion. Compared with valsartan, treatment with sacubitril/valsartan leads to a significant improvement in the quality of life in patients with FMR and HF with reduced EF, which is largely associated with a change in NT-proBNP, echocardiographic characteristics of the severity of MR and the degree of myocardial remodeling.https://www.rpcardio.online/jour/article/view/2853heart failurequality of lifeneprilysinangiotensin receptor blockers
spellingShingle A. S. Ryazanov
E. V. Shikh
O. V. Kechina
M. V. Makarovskaya
A. A. Kudryavtsev
The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
Рациональная фармакотерапия в кардиологии
heart failure
quality of life
neprilysin
angiotensin receptor blockers
title The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
title_full The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
title_fullStr The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
title_full_unstemmed The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
title_short The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
title_sort effect of angiotensin receptor and neprilysin inhibitors on quality of life in patients with heart failure with reduced ejection fraction and functional mitral regurgitation
topic heart failure
quality of life
neprilysin
angiotensin receptor blockers
url https://www.rpcardio.online/jour/article/view/2853
work_keys_str_mv AT asryazanov theeffectofangiotensinreceptorandneprilysininhibitorsonqualityoflifeinpatientswithheartfailurewithreducedejectionfractionandfunctionalmitralregurgitation
AT evshikh theeffectofangiotensinreceptorandneprilysininhibitorsonqualityoflifeinpatientswithheartfailurewithreducedejectionfractionandfunctionalmitralregurgitation
AT ovkechina theeffectofangiotensinreceptorandneprilysininhibitorsonqualityoflifeinpatientswithheartfailurewithreducedejectionfractionandfunctionalmitralregurgitation
AT mvmakarovskaya theeffectofangiotensinreceptorandneprilysininhibitorsonqualityoflifeinpatientswithheartfailurewithreducedejectionfractionandfunctionalmitralregurgitation
AT aakudryavtsev theeffectofangiotensinreceptorandneprilysininhibitorsonqualityoflifeinpatientswithheartfailurewithreducedejectionfractionandfunctionalmitralregurgitation
AT asryazanov effectofangiotensinreceptorandneprilysininhibitorsonqualityoflifeinpatientswithheartfailurewithreducedejectionfractionandfunctionalmitralregurgitation
AT evshikh effectofangiotensinreceptorandneprilysininhibitorsonqualityoflifeinpatientswithheartfailurewithreducedejectionfractionandfunctionalmitralregurgitation
AT ovkechina effectofangiotensinreceptorandneprilysininhibitorsonqualityoflifeinpatientswithheartfailurewithreducedejectionfractionandfunctionalmitralregurgitation
AT mvmakarovskaya effectofangiotensinreceptorandneprilysininhibitorsonqualityoflifeinpatientswithheartfailurewithreducedejectionfractionandfunctionalmitralregurgitation
AT aakudryavtsev effectofangiotensinreceptorandneprilysininhibitorsonqualityoflifeinpatientswithheartfailurewithreducedejectionfractionandfunctionalmitralregurgitation